240 related articles for article (PubMed ID: 36290893)
21. Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review.
Banini M; Salvestrini V; Vultaggio A; Perlato M; Mecheri V; Cerbai C; Scotti V; Matucci A; Mangoni M; Livi L; Bonomo P
Curr Oncol; 2023 Jul; 30(7):6699-6707. PubMed ID: 37504351
[TBL] [Abstract][Full Text] [Related]
22. Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma.
Ogata D; Tsuchida T
Curr Treat Options Oncol; 2019 Mar; 20(4):30. PubMed ID: 30874952
[TBL] [Abstract][Full Text] [Related]
23. High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
Rischin D; Hughes BGM; Basset-Séguin N; Schadendorf D; Bowyer S; Trabelsi Messai S; Meier F; Eigentler TK; Casado Echarren V; Stein B; Beylot-Barry M; Dalac S; Dréno B; Migden MR; Hauschild A; Schmults CD; Lim AM; Yoo SY; Paccaly AJ; Papachristos A; Nguyen JH; Okoye E; Seebach F; Booth J; Lowy I; Fury MG; Guminski A
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471711
[TBL] [Abstract][Full Text] [Related]
24. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS; Rabinowits G; Thai AA; Dunn LA; Hughes BGM; Khushalani NI; Modi B; Schadendorf D; Gao B; Seebach F; Li S; Li J; Mathias M; Booth J; Mohan K; Stankevich E; Babiker HM; Brana I; Gil-Martin M; Homsi J; Johnson ML; Moreno V; Niu J; Owonikoko TK; Papadopoulos KP; Yancopoulos GD; Lowy I; Fury MG
N Engl J Med; 2018 Jul; 379(4):341-351. PubMed ID: 29863979
[TBL] [Abstract][Full Text] [Related]
25. Infrequent liver injury from cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
Swanson L; Kassab I; Tsung I; Worden FP; Fontana RJ
Immunotherapy; 2022 Apr; 14(6):409-418. PubMed ID: 35232282
[TBL] [Abstract][Full Text] [Related]
26. Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma-A Retrospective Single-Center Study.
Kuzmanovszki D; Kiss N; Tóth B; Tóth V; Szakonyi J; Lőrincz K; Hársing J; Kuroli E; Imrédi E; Kerner T; Patyánik M; Wikonkál NM; Szabó Á; Brodszky V; Rencz F; Holló P
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762907
[TBL] [Abstract][Full Text] [Related]
27. Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients.
Van Meerhaeghe T; Baurain JF; Bechter O; Orte Cano C; Del Marmol V; Devresse A; Doubel P; Hanssens M; Hellemans R; Lienard D; Rutten A; Sprangers B; Le Moine A; Aspeslagh S
Front Nephrol; 2022; 2():1041819. PubMed ID: 37675002
[TBL] [Abstract][Full Text] [Related]
28. Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives.
Mager L; Gardeen S; Carr DR; Shahwan KT
Clin Cosmet Investig Dermatol; 2023; 16():2135-2142. PubMed ID: 37581012
[TBL] [Abstract][Full Text] [Related]
29. Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma.
Claveau J; Archambault J; Ernst DS; Giacomantonio C; Limacher JJ; Murray C; Parent F; Zloty D
Curr Oncol; 2020 Aug; 27(4):e399-e407. PubMed ID: 32905333
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study.
McLean LS; Lim AM; Bressel M; Lee J; Ladwa R; Guminski AD; Hughes B; Bowyer S; Briscoe K; Harris S; Kukard C; Zielinski R; Alamgeer M; Carlino M; Mo J; Park JJ; Khattak MA; Day F; Rischin D
Med J Aust; 2024 Feb; 220(2):80-90. PubMed ID: 38212673
[TBL] [Abstract][Full Text] [Related]
31. Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case.
Ghidini A; Santangelo D; Vaccaro G; Chillura M; Petrelli F
Oral Oncol; 2022 May; 128():105847. PubMed ID: 35367788
[TBL] [Abstract][Full Text] [Related]
32. IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.
Mallardo D; Simeone E; Festino L; Tuffanelli M; Vanella V; Trojaniello C; Vitale MG; Ottaviano M; Capone M; Madonna G; Sparano F; Cioli E; Scarpato L; Palla M; Di Trolio R; Meinardi P; Caracò C; Ferrara G; Muto P; Cavalcanti E; Ascierto PA
J Transl Med; 2023 Feb; 21(1):140. PubMed ID: 36823670
[TBL] [Abstract][Full Text] [Related]
33. Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: a retrospective analysis.
Nardone V; Napolitano S; Gagliardi F; Esposito A; Caraglia F; Briatico G; Scharf C; Ronchi A; D'Onofrio I; D'Ippolito E; Russo A; Belfiore MP; Franco R; Argenziano G; Ciardiello F; Reginelli A; Cappabianca S; Troiani T
J Am Acad Dermatol; 2024 Jun; ():. PubMed ID: 38885840
[TBL] [Abstract][Full Text] [Related]
34. Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion.
Argenziano G; Fargnoli MC; Fantini F; Gattoni M; Gualdi G; Pastore F; Pellacani G; Quaglino P; Queirolo P; Troiani T
Ther Adv Med Oncol; 2022; 14():17588359211066272. PubMed ID: 35035534
[TBL] [Abstract][Full Text] [Related]
35. Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Konidaris G; Paul E; Kuznik A; Keeping S; Chen CI; Sasane M; Xu Y; Atsou K; Ayers D; Ruiz ES; Khushalani NI; Cope S
Value Health; 2021 Mar; 24(3):377-387. PubMed ID: 33641772
[TBL] [Abstract][Full Text] [Related]
36. Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy.
Bailly-Caillé B; Levard R; Kottler D; Dompmartin A; L'Orphelin JM
Cancer Immunol Immunother; 2024 May; 73(7):118. PubMed ID: 38713217
[TBL] [Abstract][Full Text] [Related]
37. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
[TBL] [Abstract][Full Text] [Related]
38. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.
Rischin D; Khushalani NI; Schmults CD; Guminski A; Chang ALS; Lewis KD; Lim AM; Hernandez-Aya L; Hughes BGM; Schadendorf D; Hauschild A; Thai AA; Stankevich E; Booth J; Yoo SY; Li S; Chen Z; Okoye E; Chen CI; Mastey V; Sasane M; Lowy I; Fury MG; Migden MR
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34413166
[TBL] [Abstract][Full Text] [Related]
39. PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
Yakobson A; Abu Jama A; Abu Saleh O; Michlin R; Shalata W
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627069
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
Gross ND; Miller DM; Khushalani NI; Divi V; Ruiz ES; Lipson EJ; Meier F; Su YB; Swiecicki PL; Atlas J; Geiger JL; Hauschild A; Choe JH; Hughes BGM; Schadendorf D; Patel VA; Homsi J; Taube JM; Lim AM; Ferrarotto R; Kaufman HL; Seebach F; Lowy I; Yoo SY; Mathias M; Fenech K; Han H; Fury MG; Rischin D
N Engl J Med; 2022 Oct; 387(17):1557-1568. PubMed ID: 36094839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
